Journal of Multiple Sclerosis

ISSN - 2376-0389
NLM - 101654564

Kerstin Pilling

Merz Pharmaceuticals GmbH, Frankfurt A. M., Germany


  • Review Article   
    Amantadine for the Treatment of Fatigue in Multiple Sclerosis: Systematic Review and Summary of the Evidence Base
    Author(s): Kerstin Pilling and Roger F Butterworth*

    Fatigue in Multiple Sclerosis [MS] is one of the most disabling symptoms having a negative impact on disability scores and on Health-Related Quality of Life [HRQOL] occurring more frequently and with increasing severity in patients with primary or secondary-progressive disease compared to those with a relapsing-remitting presentation. With the advent of modern neuroimaging and spectroscopic methods, new insights into the pathophysiology of fatigue in MS are starting to appear in support of predominantly centrally-mediated changes. For example, abnormalities of motor-evoked potentials [MEPs] and the burden of Magnetic Resonance Imaging [MRI] lesions are independently correlated with fatigue severity in patients with MS consistent with a central origin. Moreover, the subsequent use of 18-Fluorodeoxyglucose Positron Emission Tomography [PET] and 1-H-Magnetic Resonance Spectroscopy [MRS] .. View More»
    DOI: 10.35248/2376-0389.21.8.272

    Abstract HTML PDF